
Last updated: 2026-09-16 11:44:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Cerenome, Inc. (CNSY) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $2.12, with a market capitalisation of $16.47M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.09 to $4.16. This page covers its latest market performance, valuation, price trends and company information.
$16.47M | |
$2.14 | |
$4.16 | |
$2.09 | |
$2.12 | |
1.01K | |
79.88K | |
-- | |
$4.16 | |
$2.09 | |
-- | |
-- |
Cerenome, Inc. (CNSY) is trading at $2.12 in pre-market trading as of 2026-09-16 11:31:00, up 0.14% ($0.00) from the previous close of $2.12
Pre-market trading shows how investors are pricing CNSY before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Cerenome, Inc. (CNSY) moved from $2.76 to $2.12, representing a decline of 22.94% ($0.63).
The stock traded between $2.09 and $3.00 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 85.80 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1.6%
CNSY is currently trading at $2.12, placing it 1.6% of the way from its 52-week low of $2.09 to its 52-week high of $4.16. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 28 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cerenome, Inc. (CNSY) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.